Expanding the Code of Life With New “Letters”
News May 29, 2015
The DNA encoding all life on Earth is made of four building blocks called nucleotides, commonly known as “letters,” that line up in pairs and twist into a double helix. Now, two groups of scientists are reporting for the first time that two new nucleotides can do the same thing—raising the possibility that entirely new proteins could be created for medical uses.
Synthetic biologists have been attempting for years to expand on nature’s genetic “alphabet,” consisting of the nucleotide bases cytosine, guanine, adenine and thymine—also represented by the letters “C,” “G,” “A” and “T,” respectively. But so far, the potential additions they’ve tested have shown limited promise. For example, one duo pairs up but doesn’t form a nice helix, an important criterion given that the bases would have to incorporate fairly seamlessly with the original four to be useful. Millie M. Georgiadis, Steven A. Benner and colleagues from Indiana and Florida wanted to see if another potential set of letters, “Z” (6-amino-5-nitro-2(1H)-pyridone) and “P” (2-amino-imidazo[1,2-a]-1,3,5-triazin-4(8H)one), would form a helix—and evolve.
The researchers found that multiple Z-P pairs can contribute to a double helix, just as C-G and A-T pairs do, with the same combination of flexibility and rigidity required for natural DNA to function. They also showed that the Z-P pairs integrate well with conventional pairs and that six-letter GACTZP DNA can evolve. The evolution of DNA containing the new building blocks endows the structures with new properties that could be useful in protein recognition.
Can a Common Ingredient in Laundry Detergent Help Advance Diabetes Research?News
Two oxygen-producing compounds – including one that boosts performance in some laundry detergents – might one day play a key role in helping scientists successfully build a bioartificial pancreas in the lab to cure type 1 diabetes.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE